BACKGROUND: The @entity2922 -mediated hypermetabolic response to severe @entity4808 causes @entity101 and @entity121 . We hypothesized that blockade of beta-adrenergic stimulation with @entity1169 would decrease resting energy expenditure and muscle catabolism in @entity1 with severe @entity4808 . METHODS: Twenty-five @entity1 with acute and severe @entity4808 (more than 40 percent of total body-surface area) were studied in a randomized trial. Thirteen received oral @entity1169 for at least two weeks, and 12 served as untreated controls. The dose of @entity1169 was adjusted to decrease the resting heart rate by 20 percent from each @entity1 's base-line value. Resting energy expenditure and skeletal-muscle protein kinetics were measured before and after two weeks of beta-blockade (or no therapy, in controls). Body composition was measured serially throughout hospitalization. RESULTS: @entity1 in the control group and the @entity1169 group were similar with respect to age, weight, percentage of total body-surface area burned, percentage of body-surface area with third-degree @entity4808 , and length of time from injury to metabolic study. Beta-blockade decreased the heart rates and resting energy expenditure in the @entity1169 group, both as compared with the base-line values (P<0.001 and P=0.01, respectively) and as compared with the values in the control group (P=0.03 and P=0.001, respectively). The net muscle-protein balance increased by 82 percent over base-line values in the @entity1169 group (P=0.002), whereas it decreased by 27 percent in the control group (P not significant). The fat-free mass, as measured by whole-body @entity972 scanning, did not change substantially in the @entity1169 group, whereas it decreased by a mean (+/-SE) of 9+/-2 percent in the control group (P=0.003). CONCLUSIONS: In @entity1 with @entity4808 , treatment with @entity1169 during hospitalization attenuates hypermetabolism and reverses @entity121 .

Reversal of catabolism by beta-blockade after severe XXXX .

@entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol'] @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'patient'] @entity101 :: ('MESH:D006973', 'Disease') :: ['increased energy expenditure'] @entity4808 :: ('MESH:D002056', 'Disease') :: ['burns'] @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle-protein catabolism']
@entity4808 :: (MESH:D002056,Disease) :: ['burns']
